down arrow

CONMED Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2074101013
USD
44.24
-0.11 (-0.25%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

43.9544.80

52 Week

40.2576.34
Valuation
Technical
Day's Volume

CASH

108.3 k

Shareholding (Mar 2025)

FII

10.95%

Held by 124 FIIs

DII

21.22%

Held by 72 DIIs

Promoter

1.98%

How big is CONMED Corp.?

22-Jun-2025

As of Jun 18, CONMED Corp. has a market capitalization of $1.72 billion, with net sales of $1.31 billion and a net profit of $118.75 million over the latest four quarters. The balance sheet shows shareholder's funds of $962.68 million and total assets of $2.31 billion.

As of Jun 18, CONMED Corp. has a market capitalization of 1,724.14 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,310.50 million and a net profit of 118.75 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 962.68 million and total assets of 2,306.25 million.

Read More

What does CONMED Corp. do?

22-Jun-2025

CONMED Corporation is a medical technology company that develops and sells surgical devices for minimally invasive procedures. As of March 2025, it reported net sales of $319 million and a market cap of $1.72 billion.

Overview: <BR>CONMED Corporation is a medical technology company engaged in the development, manufacturing, and sale of surgical devices and related equipment, primarily for minimally invasive procedures, within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 319 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,724.14 Million (Small Cap) <BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Dividend Yield: 142.63% <BR>Debt Equity: 0.88 <BR>Return on Equity: 9.11% <BR>Price to Book: 1.76 <BR><BR>Contact Details: <BR>Address: 525 French Road, UTICA NY: 13502 <BR>Tel: ['1 315 7978375', '1 315 6243317'] <BR>Fax: 1 302 6555049

Read More

Is CONMED Corp. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, CONMED Corp. is considered undervalued with a P/E ratio of 21 and an attractive valuation grade, but it has underperformed the S&P 500 with a year-to-date return of -24.87%, raising concerns about its growth prospects.

As of 30 June 2025, CONMED Corp. has moved from a fair to attractive valuation grade. The company appears to be undervalued, with a P/E ratio of 21, an EV to EBITDA of 13.82, and a Price to Book Value of 1.92. In comparison to peers, Globus Medical, Inc. has a P/E of 18.37, while Sanmina Corp. shows a much higher P/E of 39.80, indicating that CONMED may offer better value relative to these competitors.<BR><BR>However, it's important to note that CONMED has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -24.87% compared to the S&P 500's 12.22%. This significant underperformance may raise concerns about the company's growth prospects despite its attractive valuation metrics.

Read More

Is CONMED Corp. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, CONMED Corp. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -24.87% versus the S&P's 12.22%.

As of 1 August 2025, the technical trend for CONMED Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but remains bearish on the monthly. The RSI indicates no signal on both weekly and monthly timeframes. Bollinger Bands and moving averages are bearish, while KST shows a mildly bullish signal weekly but is bearish monthly. Dow Theory presents a mildly bearish stance weekly and mildly bullish monthly. <BR><BR>In terms of performance, CONMED has significantly underperformed the S&P 500 across all multi-period returns, with a year-to-date return of -24.87% compared to the S&P 500's 12.22%, and a one-year return of -32.35% against the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 18.38% of over the last 5 years

 
2

The company has declared negative results in Mar'2025 after 3 consecutive positive quarters

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,777 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

138.36%

stock-summary
Debt Equity

0.85

stock-summary
Return on Equity

8.88%

stock-summary
Price to Book

1.77

Revenue and Profits:
Net Sales:
343 Million
(Quarterly Results - Jun 2025)
Net Profit:
21 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.11%
0%
-19.11%
6 Months
-21.8%
0%
-21.8%
1 Year
-40.05%
0%
-40.05%
2 Years
-60.33%
0%
-60.33%
3 Years
-51.0%
0%
-51.0%
4 Years
-66.45%
0%
-66.45%
5 Years
-56.74%
0%
-56.74%

CONMED Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
CONMED Corp. Stock Plummets to New 52-Week Low of $42.50

CONMED Corp. Stock Plummets to New 52-Week Low of $42.50

CONMED Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,777 million, faces challenges in growth and profitability, evidenced by a notable decrease in net profit and ongoing scrutiny from institutional investors.

Read More
CONMED Corp. Hits New 52-Week Low at USD 45.11 Amid Decline

CONMED Corp. Hits New 52-Week Low at USD 45.11 Amid Decline

CONMED Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,777 million, faces challenges in growth despite high institutional holdings and a notable dividend yield. Its financial metrics indicate a fair valuation relative to assets.

Read More

Is CONMED Corp. technically bullish or bearish?

As of 1 August 2025, the technical trend for CONMED Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but remains bearish on the monthly. The RSI indicates no signal on both weekly and monthly timeframes. Bollinger Bands and moving averages are bearish, while KST shows a mildly bullish signal weekly but is bearish monthly. Dow Theory presents a mildly bearish stance weekly and mildly bullish monthly. In terms of performance, CONMED has significantly underperformed the S&P 500 across all multi-period returns, with a year-to-date return of -24.87% compared to the S&P 500's 12.22%, and a one-year return of -32.35% against the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
8.88%
EBIT Growth (5y)
18.38%
EBIT to Interest (avg)
3.03
Debt to EBITDA (avg)
5.39
Net Debt to Equity (avg)
0.88
Sales to Capital Employed (avg)
0.67
Tax Ratio
18.26%
Dividend Payout Ratio
18.82%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
6.55%
ROE (avg)
7.82%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
1.92
EV to EBIT
19.37
EV to EBITDA
13.82
EV to Capital Employed
1.49
EV to Sales
2.09
PEG Ratio
9.49
Dividend Yield
130.84%
ROCE (Latest)
7.70%
ROE (Latest)
9.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 100 Schemes (65.76%)

Foreign Institutions

Held by 124 Foreign Institutions (10.95%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 7.39% vs -7.12% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 256.67% vs -82.25% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "343.00",
          "val2": "319.40",
          "chgp": "7.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "54.90",
          "val2": "24.40",
          "chgp": "125.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.80",
          "val2": "8.30",
          "chgp": "-6.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.10",
          "val2": "3.30",
          "chgp": "-193.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "21.40",
          "val2": "6.00",
          "chgp": "256.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "121.60%",
          "val2": "35.90%",
          "chgp": "8.57%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.97% vs 20.44% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 105.27% vs 180.02% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,302.70",
          "val2": "1,241.00",
          "chgp": "4.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "215.50",
          "val2": "182.20",
          "chgp": "18.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "37.30",
          "val2": "39.80",
          "chgp": "-6.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "30.70",
          "val2": "-18.80",
          "chgp": "263.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "132.40",
          "val2": "64.50",
          "chgp": "105.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "126.10%",
          "val2": "105.40%",
          "chgp": "2.07%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
343.00
319.40
7.39%
Operating Profit (PBDIT) excl Other Income
54.90
24.40
125.00%
Interest
7.80
8.30
-6.02%
Exceptional Items
-3.10
3.30
-193.94%
Consolidate Net Profit
21.40
6.00
256.67%
Operating Profit Margin (Excl OI)
121.60%
35.90%
8.57%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 7.39% vs -7.12% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 256.67% vs -82.25% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,302.70
1,241.00
4.97%
Operating Profit (PBDIT) excl Other Income
215.50
182.20
18.28%
Interest
37.30
39.80
-6.28%
Exceptional Items
30.70
-18.80
263.30%
Consolidate Net Profit
132.40
64.50
105.27%
Operating Profit Margin (Excl OI)
126.10%
105.40%
2.07%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 4.97% vs 20.44% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 105.27% vs 180.02% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About CONMED Corp. stock-summary
stock-summary
CONMED Corp.
Pharmaceuticals & Biotechnology
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery and general surgery.
Company Coordinates stock-summary
Company Details
525 French Road , UTICA NY : 13502
stock-summary
Tel: 1 315 79783751 315 6243317
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."